Analysis of the key themes driving M&A activity reveals that regenerative medicine accounted for 6 pharmaceutical deals announced in Q4 2023, worth a total value of $2.4bn. The $1.2bn acquisition of Gracell Biotechnologies by AstraZeneca was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, regenerative medicine-related deal activity increased by 118% in Q4 2023 compared with the previous quarter’s total of $1.1bn and rose by 15004% as compared to Q4 2022. Related deal volume decreased by 40% in Q4 2023 versus the previous quarter and was 200% higher than in Q4 2022.
The top-ranked financial advisors supporting these M&A deals in Q4 2023 were Centerview Partners; Guggenheim Partners; SVB Financial Group with 2, 2, 2 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q4 2023 were Goodwin Procter; Gibson, Dunn & Crutcher; Chinalco Ruimin with 4, 3, 1 deals respectively.
See Also:
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.